Background: Because of the favourable safety and tolerability profiles of atazanavir (ATV) and raltegravir (RAL), attention has recently turned to the use of dual ATV plus RAL therapy as a nucleoside reverse transcriptase inhibitor-sparing treatment strategy in highly antiretroviral treatment (ART)-experienced HIV-infected patients. Methods: A retrospective observational study was carried out to assess the maintenance of viral suppression and ART tolerability in 20 highly ART-experienced patients with viral suppression, who had been switched to RAL and unboosted ATV dual therapy, using data collected during standard-of-care visits. Results: At 6, 12 and 18 months, viral load was maintained at <400 HIV RNA copies/ml, with only one participant recording a detectable viral load (150 copies/ml) at the 6-month time point. Stable CD4 + T-cell counts were maintained throughout the study period.
The use of nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimens is an attractive option for antiretroviral therapy (ART)-experienced patients, in order to alleviate NRTI-related toxicities or as a viable treatment option for patients with extensive NRTI resistance mutations. The dual combination of raltegravir (RAL) and atazanavir (ATV) has been proposed as an NRTIsparing regimen for highly ART-experienced patients with extensive treatment-related complications. Both RAL and ATV are highly potent antiretroviral drugs that are well-tolerated and have favourable toxicity profiles, especially in relation to lipid parameters [1, 2] . ATV has been demonstrated to be highly efficacious without ritonavir boosting, making it an attractive treatment option in patients with existing or previous treatmentrelated complications that preclude ritonavir use [3] .
RAL is metabolized predominantly through glucuronidation by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) [4] . ATV is a known UGT1A1 inhibitor [5] , leading to concerns that coadministration with RAL would lead to unfavourable changes in RAL pharmacokinetics. Pharmacokinetic analyses have demonstrated that RAL plasma concentrations are increased by 40-55% when coadministered with ATV [6, 7] . However, favourable toxicity results at higher RAL doses mean a reduction of RAL dose when coadministered with ATV is unnecessary [1] .
Previous and ongoing studies on ATV plus RAL therapy have recently demonstrated the efficacy of this regimen. Gupta et al. [8] Introduction follow-up, albeit in only three patients. Ripamonti et al. [9] have shown that patients on ATV plus RAL treatment achieve and maintain viral suppression and have stable CD4 + T-cell counts. No discontinuations were recorded, but two patients had virological failures within 24 weeks of commencing the regimen, one with detectable integrase resistance mutations. Longer follow-up is required to properly assess tolerability and resistance with this regimen.
The purpose of this retrospective observational study was to monitor virologically suppressed treatmentexperienced HIV-positive patients who commenced ATV plus RAL therapy, to monitor the maintenance of virological control and to identify any toxicity and tolerability issues with the use of this regimen. 
Methods

Study participants
Statistical analyses
Participants were followed-up using data from standardof-care visits for at least 18 months after commencing dual therapy. For 6-, 12-and 18-month follow-up analyses, the most recent data collected in the respective 6-month period was used for each participant. Lipid parameters were only included in the analysis if the participant was confirmed to have fasted before sample collection. All analyses were carried out on a per protocol basis. Statistical analyses were performed using Stata Statistical Software version 10.1 (Stata Corporation, College Station, TX, USA).
Results
The 20 participants were primarily male (90%), with a median age of 52 years at baseline and all were highly ART-experienced ( Table 1 ). All participants had HIV RNA<400 copies/ml immediately prior to commencing ATV plus RAL therapy. All patients were switched from protease-inhibitor-based regimens, 18 patients were on ritonavir-boosted regimens and 14 were using ATV. A total of 18 participants commenced with a regimen of 200 mg ATV twice daily and 400 mg RAL twice daily. The majority of patients had experienced previous treatmentrelated complications, including CNS and gastrointestinal side effects, lipodystrophy and virological failure.
Five patients ceased ATV plus RAL dual therapy within 18 months of commencing treatment: three patients ceased because of adverse events attributed to the new regimen. Of them, two patients reported fatigue, one of whom also reported depression (and ceased RAL treatment after 2 months), and the other reported persistent increased bilirubin levels (and ceased RAL treatment after 8 months). The third patient switched regimen because of gastrointestinal side effects after 11 months. Two patients changed regimen for other reasons: one patient added lamivudine after 12 months because of HIV-associated neurological complications and one patient switched ATV for boosted darunavir to pre-empt a potential drug-drug interaction (after 7 months). In addition, two patients did not attend the clinic in the 12-18-month period after commencement of ATV plus RAL therapy.
All participants maintained HIV RNA<400 copies/ml throughout follow-up and all participants had undetectable HIV RNA (<50 copies/ml) at 12 and 18 months (Figure 1 ). Median CD4 + T-cell counts were stable throughout the follow-up (Figure 1 ). Fasting lipids were not available for all patients at all time points; however, there was a significant decrease in fasted total cholesterol at 6 months versus baseline and this was maintained at 12 but not at 18 months ( Table 2 ). There was also a significant decrease in fasting triglycerides at 18 months. Seven patients were taking statins at baseline, two of these patients subsequently ceased statin therapy because of improved lipid profile. There was an expected significant increase in bilirubin levels associated with ATV use at 6 and 12 months compared with baseline.
During follow-up, ATV plasma levels were assessed in 18 participants. Four patients had an ATV level below the 50% inhibitory concentration (50 ng/ml). One of these patients discontinued the regimen within 2 months and a further two patients increased their ATV dose from 200 mg twice daily to 300 mg twice daily. RAL plasma levels were assessed in 12 patients during the study. All RAL measurements were above the effective 95% inhibitory concentration for this drug.
Discussion
Treatment-experienced HIV-positive patients with viral suppression who switched to unboosted ATV plus RAL therapy maintained undetectable viral loads, with no virological failures and stable CD4 + T-cell counts for 18 months. The regimen was generally well-tolerated with few side effects. The regimen also demonstrated a favourable lipid profile during the study.
The participants (who were mostly male with a median age of 52 years) were representative of treatment-experienced patients for whom this specialized treatment regimen would be considered an option at the HIV/Immunology and Infectious Diseases Clinical Services Unit.
There are concerns regarding the use of a regimen with only two active drugs and the maintenance of effective drug levels with a lower, twice-daily dose of ATV, leading to patients effectively being on monotherapy at times during dosing, and potentially resulting in the rapid development of resistance. This is of particular concern when using RAL, which represents a new drug class with a low toxicity profile and is therefore an excellent treatment option for treatment-experienced patients. Four patients in this study recorded suboptimal ATV levels, with two of these increasing ATV dose in response. A previous study demonstrated that ATV plasma levels are highly variable between individuals and that trough ATV levels were not associated with undetectable viral load [10] . Additionally, seven participants in the same study with undetectable plasma ATV trough levels (<50 ng/ml) maintained undetectable viral loads. The current study suggests that treatmentexperienced patients, who have demonstrated good adherence to therapy, can maintain viral suppression with this regimen without the rapid development of resistance, as no virological failures were seen in 18 months of follow-up.
There are additional concerns with this regimen in relation to poor CNS penetration. This could lead to insufficient viral suppression in the CNS and subsequent complications. This needs to be considered and closely monitored in future studies. In the current study, one patient had lamivudine added to their regimen because of these concerns.
The number of patients changing regimen within 12 months of commencing dual therapy was unsurprising, given that the study participants had experienced extensive complications related to long-term HIV infection and extensive antiretroviral exposure. One patient reported fatigue and depression after commencing RAL. Depression has been reported as a side effect of RAL use and might need to be closely monitored in these patients [11] . One patient changed regimen because of gastrointestinal side effects; this patient has since switched to unboosted ATV plus RAL and no further side effects have been reported. RAL and ATV have both been associated with favourable lipid profiles in HIV patients. This study suggests that favourable lipid outcomes are achievable with dual RAL plus ATV therapy. There was a significant decrease in total cholesterol at 6 and 12 months and triglycerides at 18 months follow-up and non-significant decreases in low-density lipoprotein cholesterol during this study. Although encouraging, these results were based on fasted lipids during follow-up, which were not available for all patients at all time points.
The significant increases in bilirubin levels seen in this study were expected as ATV is known to increase bilirubin via inhibition of UTG1A1. This is consistent with other studies involving this regimen and is a recognized benign complication associated with ATV use [9] .
Although this study suggests that ATV plus RAL therapy is effective at maintaining viral suppression and CD4 + T-cell counts, it is likely that this expensive and specialized regimen will be exclusively for treatmentexperienced patients with extensive treatment-related toxicities and NRTI resistance. Further studies with larger, more representative study populations and longer follow-up, combined with close monitoring for toxicities and resistance, are required to confirm the efficacy of this novel regimen.
